Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Plantarc Bio Ltd. currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are split between multiple distinct examiners and 2 distinct art units. This distribution suggests that the company's agricultural or biological innovations are being reviewed by different specialized groups within the USPTO.
KOVALENKO, MYKOLA V is the busiest examiner for the company, holding 1 pending office action. With multiple distinct examiners each managing a single pending office action, the portfolio's prosecution is decentralized. This means the company must engage with different examiner perspectives and historical allowance rates for each of its pending cases.
The involvement of 2 distinct art units for the pending actions requires the company to account for the specific tendencies and procedural nuances of each unit. Monitoring the examination trends within these separate groups will be vital for developing effective strategies. Practitioners should be prepared to tailor their arguments to the specific technical focus of each of the pending office actions.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KOVALENKO, MYKOLA V | 1 | 69.6% | +25.5% |
| ORDAZ, CHRISTIAN JOSE | 1 | 66.7% | +78.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18433835 | COMPOSITIONS AND METHODS FOR CONTROLLING PLANT GROWTH | KOVALENKO, MYKOLA V | 88d overdue |
| 18381155 | TRANSGENIC PLANTS WITH IMPROVED TRAITS | ORDAZ, CHRISTIAN JOSE | 7d |
| Art Unit | Apps |
|---|---|
| 1662 | 1 |
| 1663 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18433835 | COMPOSITIONS AND METHODS FOR CONTROLLING PLANT GROWTH | KOVALENKO, MYKOLA V | 1662 | §102 | Final Rejection | 88d overdue | Pending | Feb 06, 2024 |
| 18381155 | TRANSGENIC PLANTS WITH IMPROVED TRAITS | ORDAZ, CHRISTIAN JOSE | 1663 | §112 | Non-Final OA | 7d | Pending | Oct 17, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPlantarc Bio Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Mykola V Kovalenko has the most, with 1 of Plantarc Bio Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
